(:HARP)

Feb 10, 2024 10:51 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TGAN
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Ambrx Biopharma, Inc. (NASDAQ: AMAM)’s...
Feb 06, 2024 09:13 pm ET
INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, TARO, FFNW
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Harpoon Therapeutics, Inc. (NASDAQ:...
Feb 06, 2024 09:30 am ET
INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, JNPR, TGAN, TAST
NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 05, 2024 08:45 pm ET
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BBAI, HARP, FGH, PGTI
NEW YORK, Feb. 5, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:
Jan 25, 2024 08:03 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TARO
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Ambrx Biopharma, Inc. (NASDAQ: AMAM)’s...
Jan 24, 2024 05:17 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MDC, HARP, CVLY, AXNX
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and...
Jan 23, 2024 01:45 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates HARP, JNPR, TGAN
NEW YORK, Jan. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 19, 2024 08:00 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – GRCL, AXNX, HARP, CVLY
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Jan 19, 2024 01:15 pm ET
Kuehn Law Encourages HA, ICVX, PXD, and HARP Investors to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn...
Jan 17, 2024 12:00 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates FGH, AXNX, AMAM, HARP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:         FG Group Holdings Inc. (NYSE:...
Jan 16, 2024 10:00 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates AMAM, AXNX, HARP, GRCL
NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 16, 2024 08:05 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AX
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jan 13, 2024 08:47 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates FGH, AXNX, HARP, AMAM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:       FG Group Holdings Inc. (NYSE:...
Jan 12, 2024 07:25 pm ET
ALERT: Juan Monteverde Encourages the Shareholders of PGTI, WAVD, HARP, VIA to Take Action
NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jan 10, 2024 05:09 pm ET
HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Harpoon Therapeutics, Inc. (NasdaqCM: HARP) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Harpoon will receive $23.00 in cash for each share of Harpoon that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 10, 2024 02:07 pm ET
Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law Firm
NEW YORK, Jan. 10, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.  Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. 
Jan 09, 2024 05:36 pm ET
STOCKHOLDER ALERT: Juan Monteverde Encourages the Shareholders of HARP, VIA, RYZB, FGH to Take Action
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Jan 08, 2024 08:21 pm ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX, EAR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Harpoon Therapeutics, Inc. (NASDAQ:...
Jan 08, 2024 05:31 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AX
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jan 08, 2024 10:36 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX
NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 08, 2024 10:03 am ET
Shareholder Alert: Ademi LLP investigates whether Harpoon Therapeutics, Inc. has obtained a Fair Price in its transaction with Merck
MILWAUKEE, Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Harpoon (Nasdaq: HARP)  for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.
Jan 08, 2024 09:25 am ET
HARP Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Harpoon Therapeutics to Merck
The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $23.00 per share in cash pursuant to which Harpoon Therapeutics, Inc. (Nasdaq: HARP) (“Harpoon”) has agreed to be sold to Merck & Co., Inc. (“Merck”). The sales price...
Jan 08, 2024 08:34 am ET
HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Harpoon Therapeutics, Inc. (NASDAQ: HARP) to Merck for $23.00 per share in cash is fair to Harpoon shareholders.
Jan 08, 2024 07:30 am ET
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.
Dec 26, 2023 07:30 am ET
Harpoon Therapeutics Strengthens Leadership Team
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People...
Dec 19, 2023 07:30 am ET
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2...
Dec 11, 2023 08:15 pm ET
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported data from the Phase 1 study of HPN217 in patients with RRMM in an oral presentation at the 65th American Society of...
Nov 09, 2023 04:01 pm ET
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates....
Nov 02, 2023 09:15 am ET
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the...
Oct 25, 2023 09:31 am ET
Thinking about buying stock in VinFast Auto, Ardelyx, Harpoon Therapeutics, Mind Technology, or Ault Alliance?
NEW YORK, Oct. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VFS, ARDX, HARP, MIND, and AULT.
Oct 24, 2023 09:31 am ET
Thinking about buying stock in VinFast Auto, Ardelyx, Harpoon Therapeutics, Mind Technology, or Ault Alliance?
NEW YORK, Oct. 24, 2023 /PRNewswire/ --InvestorsObserver issues critical PriceWatch Alerts for VFS, ARDX, HARP, MIND, and AULT.
Oct 23, 2023 09:31 am ET
Thinking about buying stock in Sterling Infrastructure, Mereo BioPharma Group, RVL Pharmaceuticals, SeaStar Medical Holding, or Harpoon Therapeutics?
NEW YORK, Oct. 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STRL, MREO, RVLP, ICU, and HARP.
Oct 23, 2023 07:17 am ET
Harpoon Therapeutics Announces Up to $150 Million Private Placement
Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a securities purchase agreement for a private placement in public equity...
Oct 21, 2023 11:31 am ET
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer...
Oct 16, 2023 04:05 pm ET
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a live webcast at 8:00 a.m. ET / 2:00 p.m. CEST on Monday, October 23, 2023 to review interim...
Oct 09, 2023 04:17 pm ET
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung...
Sep 28, 2023 03:00 am ET
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the presentation of interim data for the 2.15 to 12 mg target dose cohorts from its Phase 1 clinical trial...
Sep 15, 2023 07:15 am ET
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer (SCLC) in an ongoing Phase 1/2 trial of HPN328, a DLL3...
Sep 13, 2023 04:05 pm ET
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’...
Sep 06, 2023 07:30 am ET
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose...
Sep 05, 2023 08:05 am ET
Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will host an in-person event “DLL3 Market Opportunity and KOL Discussion of HPN328”, in New York...
Sep 05, 2023 08:00 am ET
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences in September. Citi’s 18th Annual BioPharma...
Aug 09, 2023 04:01 pm ET
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “Following...
Aug 03, 2023 07:30 am ET
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences: A corporate presentation at the Canaccord...
Aug 01, 2023 07:30 am ET
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 years of...
Jul 10, 2023 09:00 am ET
Replicate Bioscience Appoints Rachael Lester as Chief Business Officer
Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team
Jun 27, 2023 07:30 am ET
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the safety,...
May 11, 2023 04:30 pm ET
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “Harpoon is...
Apr 18, 2023 01:30 pm ET
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented preclinical data for two of its key clinical programs, HPN328 and HPN217, in three poster presentations at the...
Apr 17, 2023 01:30 pm ET
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented preclinical data on two new development candidates from the proprietary ProTriTAC™ platform in TROP2- and...
Apr 10, 2023 04:05 pm ET
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that Julie Eastland, President and Chief Executive Officer, and Luke Walker, M.D., Chief Medical Officer, will...
Mar 27, 2023 04:05 pm ET
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update....
Mar 27, 2023 04:02 pm ET
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it has closed a private placement of redeemable preferred stock and warrants to purchase...
Mar 14, 2023 06:21 pm ET
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it will present data from five preclinical investigations in poster presentations at the American Association...
Feb 07, 2023 07:30 am ET
Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will present at the virtual SVB Securities Global Biopharma Conference. The corporate presentation...
Dec 12, 2022 07:34 am ET
Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals?
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTGM, HARP, ACER, APVO, and TNXP.
Dec 11, 2022 10:00 am ET
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory...
Dec 05, 2022 07:30 am ET
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review updated interim results of its Phase 1 HPN217 clinical...
Nov 21, 2022 04:59 pm ET
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. The...
Nov 14, 2022 04:01 pm ET
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided an update on strategic priorities and reported financial results for the third quarter ended September 30, 2022....
Nov 03, 2022 09:09 am ET
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in...
Oct 04, 2022 07:30 am ET
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Luke Walker, M.D., as Chief Medical Officer. Dr. Walker will lead the clinical development...
Sep 19, 2022 04:05 pm ET
Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Lauren Silvernail to its Board of Directors and as the Chairperson of its Audit Committee. “We...
Sep 01, 2022 07:30 am ET
Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in three upcoming investor conferences: Conduct one-on-one investor meetings at...
Aug 10, 2022 04:01 pm ET
Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “We continue to focus...
Aug 02, 2022 07:30 am ET
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences: A panel discussion, “For Your IOnly –...
Jul 06, 2022 07:30 am ET
Harpoon Therapeutics Expands Leadership Team
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Wendy Chang to Senior Vice President, Human Resources and Banmeet Anand, Ph.D., to Senior Vice...
May 26, 2022 05:00 pm ET
Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced interim safety and efficacy data from the ongoing dose escalation and expansion study evaluating HPN328, Harpoon’s...
May 12, 2022 04:05 pm ET
Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “We continue to...
May 02, 2022 09:00 am ET
Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab...
Apr 12, 2022 07:30 am ET
Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with preclinical data for its TriTAC-XR T cell engager platform at the American Association for Cancer...
Apr 07, 2022 04:05 pm ET
Harpoon Therapeutics Announces Leadership Change
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, 2022. Dr. Sacks will...
Apr 07, 2022 07:30 am ET
Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual...
Mar 10, 2022 04:04 pm ET
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “We...
Mar 07, 2022 07:30 am ET
Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN328, a delta like ligand...
Mar 02, 2022 07:30 am ET
Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HPN217, a BCMA-targeting...
Feb 09, 2022 07:30 am ET
Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare...
Jan 11, 2022 08:00 am ET
Harpoon Therapeutics Provides Pipeline Development Milestones for 2022
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline milestone update on its TriTAC development programs. “We are excited to begin 2022 with a catalyst rich...
Dec 13, 2021 04:05 pm ET
Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms   
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline update on its programs, including the interim data presented from the ongoing dose-escalation portion of...
Dec 11, 2021 09:00 am ET
Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with interim data from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients...
Dec 07, 2021 07:30 am ET
Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review the clinical status and provide an update on its pipeline...
Nov 12, 2021 07:00 am ET
Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with preclinical data on its TriTAC-XR T cell engager platform at the 36th Annual Meeting of the Society...
Nov 10, 2021 04:05 pm ET
Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “I look...
Nov 09, 2021 04:01 pm ET
Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that management will participate in two upcoming virtual investor conferences: A fireside chat at...
Nov 04, 2021 09:00 am ET
Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology...
Oct 26, 2021 04:15 pm ET
Harpoon Therapeutics Announces Change to Management Team and Board of Directors
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Julie Eastland has been named President and Chief Executive Officer, effective November 8, 2021. Ms....
Oct 05, 2021 07:30 am ET
Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that an abstract with preclinical data of its TriTAC-XR T cell engager platform has been accepted for...
Sep 02, 2021 07:30 am ET
Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in three upcoming...
Aug 05, 2021 04:05 pm ET
Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “The...
Aug 03, 2021 04:05 pm ET
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming...
Jun 04, 2021 04:00 pm ET
Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provided a pipeline update on its four clinical stage programs, including updating the interim data presented...
Jun 04, 2021 09:00 am ET
Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today presented interim data from the ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in patients with...
May 19, 2021 05:02 pm ET
Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at the 2021 American...
May 06, 2021 04:04 pm ET
Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. “We...
Apr 28, 2021 04:05 pm ET
Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at...
Apr 10, 2021 08:30 am ET
Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the availability of three poster presentations at the American Association for Cancer Research (AACR)...
Mar 24, 2021 05:09 pm ET
Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is an experienced biotech...
Mar 11, 2021 01:16 pm ET
Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research...
Mar 10, 2021 04:05 pm ET
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate...
Mar 09, 2021 07:30 am ET
Harpoon Therapeutics to Participate in 33rd Annual Roth Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a panel discussion...
Mar 04, 2021 07:30 am ET
Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update on...
Feb 17, 2021 07:30 am ET
Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at...
Jan 13, 2021 07:30 am ET
Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the...
Jan 11, 2021 04:01 pm ET
Harpoon Therapeutics Announces Closing of Public Offering of Common Stock
Harpoon Therapeutics, Inc. (Nasdaq: HARP) announced today the closing of its underwritten public offering of 6,764,704 shares of its common stock, which includes 882,352 shares sold upon the underwriters’ full exercise of their option to purchase...
Jan 06, 2021 09:44 pm ET
Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock
Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share. Harpoon Therapeutics expects that the gross proceeds...
Jan 06, 2021 04:01 pm ET
Harpoon Therapeutics Announces Proposed Public Offering of Common Stock
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it has commenced an underwritten public offering of its common stock. In connection with the...
Jan 04, 2021 07:30 am ET
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC®, in a...
Dec 08, 2020 08:00 am ET
Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provided a pipeline update and reported a confirmed partial response based on RECIST v1.1 criteria for its most...
Dec 07, 2020 04:05 pm ET
Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will host a conference call and webcast to review the status and provide a clinical update for...
Nov 16, 2020 07:30 am ET
Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at...
Nov 12, 2020 04:15 pm ET
Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented preclinical data on HPN601 for the treatment of solid tumors at the 35th Society for Immunotherapy of Cancer (SITC)...
Nov 09, 2020 07:30 am ET
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming...
Nov 05, 2020 07:30 am ET
Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC™ Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced today that the preclinical data on HPN601 for the treatment of solid tumors has been accepted for oral presentation at the...
Nov 04, 2020 04:05 pm ET
Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update. “We...
Nov 03, 2020 07:30 am ET
Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Omer Siddiqui as Vice President, Development Operations and Project Management. Mr....
Sep 09, 2020 04:05 pm ET
Harpoon Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at...
Sep 02, 2020 07:30 am ET
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming...
Aug 26, 2020 07:30 am ET
Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Karin Ann Thacker, M.Sc., as Vice President, Regulatory Affairs and Quality Assurance....
Aug 05, 2020 04:05 pm ET
Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate update. “Our...
Aug 05, 2020 07:30 am ET
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming...
Jul 02, 2020 07:30 am ET
Harpoon Therapeutics Announces Changes to Board of Directors
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of veteran biotech executive Joanne Viney, Ph.D., to its board of directors as an...
Jun 17, 2020 07:30 am ET
Harpoon Therapeutics Updates Information for its Participation in Two Upcoming Virtual Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced new information regarding its participation in two upcoming investor virtual conferences. Gerald McMahon,...
Jun 11, 2020 07:30 am ET
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming...
May 29, 2020 08:00 am ET
Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today presented interim data from the ongoing dose-escalation portion of a Phase 1 trial for HPN424 in patients with...
May 22, 2020 07:30 am ET
Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that interim Phase 1 data for HPN424 for prostate cancer will be presented at the American Society of...
May 06, 2020 04:05 pm ET
Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the first quarter ended March 31, 2020 and provided a corporate update. “Harpoon...
Apr 27, 2020 06:30 am ET
Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN217 in a Phase 1/2 clinical trial focused on relapsed,...
Apr 01, 2020 07:30 am ET
Harpoon Therapeutics Appoints Two New Members to Its Board of Directors
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it has appointed Andrew R. Robbins and Joseph S. Bailes, M.D., to its Board of Directors. Among his...
Mar 12, 2020 04:05 pm ET
Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate...
Mar 05, 2020 07:30 am ET
Harpoon Therapeutics to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it will report fourth quarter and full year 2019 financial results and provide a corporate update on...
Feb 20, 2020 07:30 am ET
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming...
Nov 26, 2019 07:30 am ET
Harpoon Therapeutics to Participate in the Piper Jaffray Healthcare Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at...
Nov 21, 2019 04:00 am ET
Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, today announced an exclusive worldwide option and...
Nov 12, 2019 04:05 pm ET
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will present at two upcoming investor...
Nov 06, 2019 04:05 pm ET
Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter and nine months ended September 30, 2019 and provided a corporate...
Oct 29, 2019 12:30 pm ET
Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today presented a poster showing preclinical data supporting HPN328 as a treatment for small cell lung cancer (SCLC) at...
Oct 22, 2019 04:05 pm ET
Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that an abstract regarding HPN328 for the treatment of small cell lung cancer has been accepted for...
Aug 28, 2019 04:05 pm ET
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming...
Aug 05, 2019 04:05 pm ET
Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the second quarter and six months ended June 30, 2019 and provided a corporate...
Jul 31, 2019 04:05 pm ET
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will present at two upcoming investor...
Jun 20, 2019 04:05 pm ET
Selecta Biosciences Announces Appointment of Scott D. Myers to Board of Directors
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the appointment of Scott D....
May 09, 2019 08:30 am ET
Harpoon Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the first quarter ended March 31, 2019 and provided a corporate update. “Harpoon...
Apr 18, 2019 07:30 am ET
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that the first patient has been dosed with HPN536 in a Phase 1/2a clinical trial initially focused on...
Mar 14, 2019 04:05 pm ET
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a corporate update.
Mar 13, 2019 04:07 pm ET
Harpoon Therapeutics to Participate in Upcoming William Blair Cancer Immunotherapy Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in the William Blair...
Mar 07, 2019 04:05 pm ET
Harpoon Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it will report fourth quarter and full year 2018 financial results and provide a corporate update on...
Feb 20, 2019 07:30 am ET
Harpoon Therapeutics to Present at SVB Leerink Global Healthcare Conference
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that Gerald McMahon, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.